The Global Research and Development Headquarters of CP Group was officially completed and put into operation in Shanghai, with a total investment of 1.8 billion yuan.

On June 6th, the Zhen Dai Tian Qing Global R&D Headquarters with a total investment of 1.8 billion RMB officially opened in the Minhang District of Shanghai. Zhen Dai Tian Qing Pharmaceutical Group is a core enterprise under the leading Hong Kong-listed pharmaceutical company China Biotech. In 2023, Zhen Dai Tian Qing announced that the global R&D headquarters will be located in Minhang. The headquarters covers an area of 58.2 acres with a building area of 186,000 square meters, including one R&D complex, two core laboratory buildings, and one talent apartment building. On the same day, Xie Chengrun, CEO of China Biotech and Chairman of Zhen Dai Tian Qing Pharmaceutical Group, also announced plans to build an interdisciplinary and cross-industry innovation incubation park leveraging the location and industrial advantages of Minhang, radiating the Yangtze River Delta, driving the upstream and downstream industries, and creating a source of innovation for the biopharmaceutical industry in the Yangtze River Delta region.